Antengene
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 28.8m | 160m | 67.3m | 95.3m | 284m | 405m |
| % growth | - | - | 457 % | (58 %) | 42 % | 198 % | 43 % |
| EBITDA | (2.9b) | (644m) | (573m) | (551m) | (356m) | (414m) | (404m) |
| % EBITDA margin | - | (2237 %) | (358 %) | (818 %) | (373 %) | (146 %) | (100 %) |
| Profit | (2.9b) | (656m) | (601m) | (581m) | (336m) | (351m) | (344m) |
| % profit margin | - | (2279 %) | (376 %) | (864 %) | (352 %) | (123 %) | (85 %) |
| EV / revenue | - | 106.4x | 8.4x | 3.5x | 4.1x | 1.4x | 1.0x |
| EV / EBITDA | -2.3x | -4.8x | -2.3x | -0.4x | -1.1x | -0.9x | -1.0x |
| R&D budget | 348m | 405m | 488m | 406m | - | - | - |
| R&D % of revenue | - | 1408 % | 305 % | 603 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $21.0m | Series A | |
* | $120m | Series B | |
$97.0m Valuation: $600m -13.6x EV/LTM EBITDA | Series C | ||
| N/A | $340m | IPO | |
| Total Funding | $238m | ||
Related Content
Recent News about Antengene
EditAntengene is a biopharmaceutical company focused on developing and commercializing innovative oncology and immunology therapies. The company serves patients with cancer and viral diseases, operating primarily in the Asia-Pacific region and expanding globally. Antengene's business model involves research and development of novel drugs, conducting clinical trials, and partnering with other pharmaceutical companies for commercialization. Revenue is generated through the sale of proprietary drugs and licensing agreements. The company leverages its strong pipeline of clinical-stage assets and strategic collaborations to address unmet medical needs in oncology and immunology.
Keywords: biopharmaceutical, oncology, immunology, cancer, viral diseases, clinical trials, Asia-Pacific, drug development, licensing, partnerships.